Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Commentary|Articles|July 15, 2026
Kerry Rogers, MD, Talks BTK Inhibitor Sequencing, Cost, Access in CLL
Author(s)Maggie L. Shaw, Kerry Rogers, MD
Fact checked by: Laura Joszt, MA
Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
The evolving Bruton tyrosine kinase (BTK) inhibitor landscape for
Related to this article
This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
The EEOC is reportedly preparing to narrow Pregnant Workers Fairness Act rules; no revised rule has been published as of yet.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement